WCLC 2026

Zongertinib, Sevabertinib, and T-DXd: A Patient-Specific Approach

Stephen Liu, MD, chief of hematology and oncology at Georgetown University, considers how to sequence zongertinib, sevabertinib, and trastuzumab deruxtecan in H...

Zongertinib, Sevabertinib, and T-DXd: A Patient-Specific Approach

Latest Conference News

DESTINY-Lung04 Moves T-DXd Into First-Line HER2-Mutant NSCLC

DESTINY-Lung04 Moves T-DXd Into First-Line HER2-Mutant NSCLC

Stephen Liu, MD, chief of hematology and oncology at Georgetown University, discusses the phase 3 DESTINY-Lung04 trial of first-line trastuzumab deruxtecan in H...

Practice-Changing SCLC Findings From WCLC 2026

Practice-Changing SCLC Findings From WCLC 2026

Stephen Liu, MD, chief of hematology and oncology at Georgetown University, reviews important small cell lung cancer findings from WCLC 2026. He discusses how t...

Choosing Among Zongertinib, Sevabertinib, and T-DXd in HER2-Mutant NSCLC

Choosing Among Zongertinib, Sevabertinib, and T-DXd in HER2-Mutant NSCLC

Yasir Elamin, MD, an associate professor of thoracic medical oncology at The University of Texas MD Anderson Cancer Center, compares zongertinib, sevabertinib, ...

HER2-Mutated Lung Cancer: CNS Activity, Testing, and Treatment Sequencing

HER2-Mutated Lung Cancer: CNS Activity, Testing, and Treatment Sequencing

Dr. Yasir Elamin reviews key considerations for treating patients with HER2-mutated lung cancer, including the high frequency of CNS metastases and the importan...

COPERNICUS: Improving Tolerability of Amivantamab-Lazertinib

COPERNICUS: Improving Tolerability of Amivantamab-Lazertinib

Balazs Halmos, MD, reviews findings from COPERNICUS evaluating how subcutaneous amivantamab and proactive supportive care can improve the real-world delivery of...

Dr. Balazs Halmos on Combination Strategies in EGFR-Mutated Lung Cancer

Dr. Balazs Halmos on Combination Strategies in EGFR-Mutated Lung Cancer

Balazs Halmos, MD, examines how clinicians can choose among emerging targeted treatment options for advanced EGFR-mutated lung cancer when direct head-to-head c...

MAVERICK, B7-H3 ADCs, and Tarlatamab: Key SCLC Takeaways From WCLC 2026

MAVERICK, B7-H3 ADCs, and Tarlatamab: Key SCLC Takeaways From WCLC 2026

Millie Das, MD, of Stanford University and the VA Palo Alto Health Care System, reviews key small cell lung cancer findings from the IASLC 2026 World Conference...

DESTINY-Lung04 Advances First-Line T-DXd in HER2-Mutant NSCLC

DESTINY-Lung04 Advances First-Line T-DXd in HER2-Mutant NSCLC

Yasir Elamin, MD, an associate professor of thoracic medical oncology at The University of Texas MD Anderson Cancer Center, discusses results from the phase 3 D...